Drug Profile


Alternative Names: EMAB-6; LFB-R603; R603; TG-1101; TGTX-1101; Utuxin

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LFB Biotechnologies; rEVO Biologics
  • Developer Johns Hopkins University; LFB Biotechnologies; TG Therapeutics Inc
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Diffuse large B cell lymphoma; MALT lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple sclerosis
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Neuromyelitis optica

Most Recent Events

  • 03 Aug 2017 TG Therapeutics signs a Special Protocol Assessment (SPA) agreement with the US FDA for the design of two phase III studies ULTIMATE I and ULTIMATE II in relapsing multiple sclerosis
  • 01 Aug 2017 TG Therapeutics plans to initiate two phase III trials ULTIMATE I and ULTIMATE II for relapsing Multiple sclerosis before end of Q3 2017
  • 28 Jun 2017 TG Therapeutics initiates enrolment in a phase II trial for Chronic lymphocytic leukaemia (Combination therapy) in USA (IV) (NCT03207256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top